PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology (NASDAQ:PDSB) reported first-quarter fiscal results connected Wednesday. The transcript from the company's first-quarter net telephone has been provided below.

Benzinga APIs supply real-time entree to net telephone transcripts and fiscal data. Visit https://www.benzinga.com/apis/ to larn more.

The afloat net telephone is disposable astatine https://viavid.webcasts.com/starthere.jsp?ei=1761437&tp_key=6d561d3af2

Summary

PDS Biotechnology reported a nett nonaccomplishment of $7.3 cardinal for Q1 2026, an betterment from $8.5 cardinal successful Q1 2025, with reduced probe and improvement and wide administrative expenses.

The institution made important advancement successful its objective programs, notably amending the versatile 003 proceedings to see progression-free endurance arsenic a superior endpoint, perchance reducing proceedings duration and costs.

PDS Biotechnology strengthened its intelligence spot with caller patents for PDS0101 successful the US and Japan, extending marketplace extortion into the 2040s.

Positive results were reported from trials involving PDS01 ADC successful prostate and colorectal cancer, supporting its imaginable crossed aggregate coagulated tumor types.

Management highlighted the promising aboriginal outlook, focusing connected advancing PDS0101 arsenic a attraction for HPV 16 affirmative cancers, with late-stage trials successful collaboration with cardinal institutions.

Full Transcript

OPERATOR

Greetings and invited to The PDS Biotech archetypal 4th 2026 net league call. At this time, each participants are successful a perceive lone mode. A question and reply league volition travel the ceremonial presentation. If anyone should necessitate operating assistance, delight property Star zero connected your telephone keypad. It is present my pleasance to present your host, Dean Schwartz. Thank you. You may.

Dean Schwartz (Moderator)

Thank you, Operator. Good greeting everyone and invited to PDS Biotech's archetypal 4th 2026 results and objective programs. Update telephone I'm joined connected the telephone contiguous by the pursuing members of the company's absorption team. Dr. Frank Baduodeau, Chief Executive Officer, Dr. Kirk Sheppard, Chief Medical Officer and Lars Bozgaard, Chief Financial Officer. Dr. Baduodeau and Dr. Sheppard volition supply an overview of the company's caller highlights successful its objective improvement program, and Mr. Bozgaard volition reappraisal the fiscal results for the 4th ended March 31, 2026. Following management's prepared remarks, we volition instrumentality questions from covering analysts. As a reminder, during this call, we volition beryllium making guardant looking statements which are taxable to assorted risks and uncertainties that could origin our existent results to disagree materially from these statements. Any specified statements should beryllium considered successful conjunction with cautionary statements successful our property releases and hazard factors discussed successful our filings with the SEC, including our quarterly reports connected Form 10Q and yearly study connected Form 10K and cautionary statements made during this call. We presume nary work to update immoderate of these guardant looking statements oregon information. Now I'd similar to crook the telephone implicit to Dr. Baduodeau, Frank.